多发性骨髓瘤患者异基因造血细胞移植前后[18F]FDG-PET/CT的预后价值
该回顾性分析评估了45例经重度预处理的多发性骨髓瘤患者在异基因造血细胞移植前及27例移植后约100天行[18F]FDG-PET/CT的预后价值。PET/CT阴性是移植前后无进展生存和总生存的有利预后因素,高FDG摄取(SUVmax>6.5)、局灶性病灶数>3及髓外病变为不良预后因素。移植后疗效评估时,[18F]FDG-PET/CT在IMWG标准之外具有补充预后价值。
要点
- 移植前或移植后PET/CT阴性预示更长的无进展生存和总生存(PFS和OS:移植前P<0.001,移植后P<0.005)。
- SUVmax>6.5者总生存较SUVmax<6.5者显著缩短(5.0±1.1个月 vs 未达最长122.0个月,P<0.001)。
- 局灶性病灶数>3及髓外病变在移植前后均为不良预后因素。
核心结论
- 异基因造血细胞移植前及移植后短期内行[18F]FDG-PET/CT是多发性骨髓瘤患者无进展生存和总生存的有力预测因素。
研究设计与样本
- 回顾性分析纳入45例经重度预处理的多发性骨髓瘤患者,评估异基因造血细胞移植前及27例移植后约100天的[18F]FDG-PET/CT扫描。
- 所有扫描均定性及半定量评估活动性疾病的存在,血清学反应按国际骨髓瘤工作组(IMWG)标准记录。
主要发现
- 移植前或移植后PET/CT阴性是无进展生存和总生存的有利预后因素(PFS和OS:移植前P<0.001,移植后P<0.005)。
- 高FDG摄取(SUVmax>6.5)者总生存较SUVmax<6.5者显著缩短(5.0±1.1个月 vs 未达最长122.0个月,P<0.001)。
- 局灶性病灶数>3在移植前与PFS和OS均相关(P<0.001),移植后与PFS相关(P<0.001)、与OS相关P=0.139。
- 髓外病变在移植前后均为不良预后因素。
- 移植后疗效评估时,[18F]FDG-PET/CT在IMWG标准之外具有补充预后价值。
关键数值与推荐
- PET/CT阴性定义为无活动性疾病,为有利预后因素(PFS和OS:移植前P<0.001,移植后P<0.005)。
- SUVmax阈值6.5:>6.5者总生存5.0±1.1个月,<6.5者未达最长122.0个月(P<0.001)。
- 局灶性病灶数阈值3:>3为不良预后因素(移植前PFS和OS P<0.001;移植后PFS P<0.001,OS P=0.139)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F-2'-deoxy-2'-fluorodeoxyglucose ([18F]FDG) in MM patients shortly before and ~100 days after allogeneic hematopoietic cell transplantation (allo-HCT). METHODS: In this retrospective analysis, we evaluated [18F]FDG-PET/CT-scans of 45 heavily pre-treated MM patients before and 27 patients after scheduled allo-HCT. All scans were qualitatively and semi-quantitatively assessed for the presence of active disease. Serological response was recorded according to International Myeloma Working Group (IMWG) criteria. Progression-free (PFS) and overall survival (OS) were correlated with different PET/CT-derived parameters, such as presence, number and maximum standardized uptake value (SUVmax) of focal myeloma lesions. The impact of extramedullary disease on patient outcome was also assessed. RESULTS: PET/CT negativity -prior to or following allo-HCT- was a favorable prognostic factor for progression-free and overall survival (both, PFS and OS: pre-HSCT p < 0.001, post-HCT p < 0.005). High FDG-uptake (SUVmax > 6.5) revealed a significantly shortened survival compared to patients with a lower SUVmax (<6.5) (OS, 5.0 ± 1.1 m vs. not reached - longest 122.0 m; p < 0.001). Moreover, our data prove that a higher number (>3) of focal lesions (pre-HCT: both PFS and OS: p < 0.001; post-HCT PFS: p < 0.001, OS: p = 0.139) as well as the presence of extramedullary disease serve as adverse prognostic factors prior to and after allo-HCT. At response assessment after allo-HCT, [18F]FDG-PET/CT had a complementary value in prognostication in addition to IMWG criteria alone. CONCLUSION: [18F]FDG-PET/CT before and shortly after allogeneic HCT is a powerful predictor for progression-free and overall survival in MM patients.
引用
- Stolzenburg A, Lückerath K, Samnick S, et al. Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Eur J Nucl Med Mol Imaging. 2018. PMID: 29610955. doi:10.1007/s00259-018-3997-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。